In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

John Simpson: Reluctant Entrepreneur

Executive Summary

John Simpson never set out to be a physician and still does not consider himself a businessman; yet he is a leading interventional cardiologist and has launched more than a half dozen successful device companies. Simpson takes pride in building successful teams, enabling him to delegate the engineering and business responsibilities to others, while focusing on what he does best: figuring out how to better treat the patient. He is perhaps best known for developing over-the-wire angioplasty through his first company, ACS, and has followed that with companies involved with ultrasound (CVIS), atherectomy (DVI and Fox Hollow), vascular closure (Perclose), and chronic total occlusions (LuMend). Simpson remains iconoclastic when it comes to patient care issues. So although angioplasty is where he made his name, he remains suspicious of stents and hopes through his current venture, Fox Hollow, to minimize their use.

You may also be interested in...



Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?

Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?

Atherectomy Devices: At the Cutting Edge of Peripheral Vascular Disease

In the past, many medical device companies have seen PVD as a smaller offshoot of the coronary market and have sought to tap the opportunity primarily as a kind of commercial and technological second thought. Thus, they've largely tried to adapt devices developed for the coronary vasculature to peripheral applications-stents are the best example-only to fail, not because the market for PVD devices isn't there, but because significant differences between the anatomy of the peripheral and coronary vasculature mean that coronary devices don't always translate well to this new area. Now, though, as suggested by the success of FoxHollow, which recently went public, one of the most product areas for PVD may be a technology that has been around for a long time in coronary therapy but has gained a shaky reputation: atherectomy. New companies with interventional plaque clearing technologies-Cardiovascular Systems, Pathway Medical, and Minnow Medical-are thus targeting PVD first, coronary arteries, second.

An Interview with Simon Stertzer, MD: Angioplasty Pioneer

The physician who performed the first US angioplasty and helped launch the most successful stent start-up discusses interventional cardiology--past, present and future.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel